News

Company News & Events

ORYZON AT BIOSPAIN 2016

29 September 2016

Today ORYZON presented “Current challenges and New Therapeutic Prospects to fight Alzheimer’s disease”, a panel discussion at BIOSPAIN 2016 in Bilbao, Spain. The panel was moderated by Oryzon’s Chief Scientific Officer Dr. Tamara Maes and counted with the participation of Prof. Harald Hampel, world authority on Alzheimer’s disease and related neurodegenerative diseases and member of Oryzon’s Scientific Advisory Board, Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF), and Dr. Gurutz Linazosoro, Director of the Centro de Investigación Parkinson y Alzheimer Policlínica Gipuzkoa, Scientific Director of CITA Alzheimer Foundation and CEO of VIVE bioTECH. A broad discussion with different views on therapeutic options, diagnostics tools, experimental drugs and lessons learned and way to proceed to combat Alzheimer’s disease.

ORYZON AT BIOSPAIN 2016 - Current challenges and New Therapeutic Prospects to fight Alzheimer’s disease

ORYZON AT BIOSPAIN 2016 - Stand


 

Today ORYZON´s Chief Executive Officer Carlos Buesa moderated the panel titled “IPOs for High Growth Biotech Companies” at BIOSPAIN 2016 in Bilbao, Spain. The panel counted with the participation of sell-side experts as Jonathan Senior from STIFEL (UK) and Pedro Arranz from Solventis (Spain), the buy-side as Sebastian Groyer from Seventure Partners (France) and the experience of two European public companies, Miguel Mulet from Tigenix (Belgium) and Oryzon (Spain). The discussion focused on EU and US IPOs performance in 2016, costs of up-listing and dual listing benefits, and also the prospects for the financial markets in 2017.

ORYZON AT BIOSPAIN 2016 - IPOs for High Growth Biotech Companies

Posted In: 
Investors
News

Share this story